Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study First FcRn blocker to demonstrate sustained ...

The Sanford PLEDGE Study has reached a major milestone as it explores a blood test to identify children at risk of developing ...

US billionaire Bryan Johnson underwent his first total plasma exchange (TPE) to 'remove toxins' from his body. He said that he replaced it with albumin, a protein made by the liver.

The clinical use of TRAb measurements for the diagnosis and follow-up of AITD remains a matter of controversy and differs geographically. The differential diagnosis of hyperthyroidism can be ...

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population ...

Immunovant, Inc. shifts focus to anti-FcRn antibody IMVT-1402, but high R&D costs and uncertainty warrant caution for ...